Showing results (71-80 of 133) with videos related to

Sort By:
Pageof 14
Rheumatology International|August 31, 2013
Factors associated with time to diagnosis in early rheumatoid arthritisCheryl Barnabe, Juan Xiong, Janet E Pope, et al.
ACR Open Rheumatology|July 1, 2021
Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass IndexVivian P Bykerk, Andrew Blauvelt, Jeffrey R Curtis, et al.
Arthritis Research & Therapy|November 7, 2008
Analysis of the precision and sensitivity to change of different approaches to assess cartilage loss by quantitative MRI in a longitudinal multicentre clinical trial in patients with knee osteoarthritisJean-Pierre Raynauld, Johanne Martel-Pelletier, François Abram, et al.
Rheumatology and Therapy|May 24, 2021
Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension StudyAlvin F Wells, Bochao Jia, Li Xie, et al.
Therapeutic Advances in Musculoskeletal Disease|March 13, 2019
Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in Canadian practice: 2-year results from the observational FαsT-CAN studyLouis Bessette, Boulos Haraoui, Andrew Chow, et al.
The Journal of Rheumatology|October 3, 2014
Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritisLillian Barra, Janet E Pope, John E Orav, et al.
Rheumatology and Therapy|November 1, 2024
Tofacitinib Safety and Effectiveness in Canadian Patients with Rheumatoid Arthritis by Cardiovascular Risk Enrichment: Subanalysis of the CANTORAL StudyBoulos Haraoui, Majed Khraishi, Denis Choquette, et al.
RMD Open|June 9, 2021
Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift)Stanley B Cohen, Janet Pope, Boulos Haraoui, et al.
Cartilage|June 13, 2015
Total Knee Replacement as a Knee Osteoarthritis Outcome: Predictors Derived from a 4-Year Long-Term Observation following a Randomized Clinical Trial Using Chondroitin SulfateJean-Pierre Raynauld, Johanne Martel-Pelletier, Marc Dorais, et al.
Seminars in Arthritis and Rheumatism|September 5, 2018
A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis populationAlan J Kivitz, Stanley Cohen, Edward Keystone, et al.
Pageof 14